Discontinued — last reported Q3 '23
Products & Services · Research and development expense
ADUHELM — Research and development expense
Year-over-year, this metric declined by 100.0%, from $83.75M to $0.00.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ3 2023
Rolls up toR&D
How to read this metric
High spending indicates a commitment to innovation, but sustained high levels without revenue growth may signal inefficiency.
Detailed definition
This metric captures the total costs incurred for the research, development, and clinical trials of a specific product o...
Peer comparison
Benchmark against industry peers in biotechnology to assess R&D efficiency relative to pipeline success.
Metric ID:
biib_segment_aduhelm_research_and_development_expenseHistorical Data
7 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | |
|---|---|---|---|---|---|---|---|
| Value | $83.75M | $83.75M | $83.75M | $83.75M | $335.00M | $0.00 | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +300.0% | -100.0% | — |
| YoY Change | — | — | — | — | +300.0% | -100.0% | -100.0% |
Range$0.00 – $335.00M
CAGR-100.0%
Avg YoY Growth+33.3%
Median YoY Growth-100.0%
Current Streak2 quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's aduhelm — research and development expense?
- Biogen (BIIB) reported aduhelm — research and development expense of $0.00 in Q3 2023.
- How has Biogen's aduhelm — research and development expense changed year-over-year?
- Biogen's aduhelm — research and development expense decreased by 100.0% year-over-year, from $83.75M to $0.00.
- What does aduhelm — research and development expense mean?
- The total spending on research and development for a specific product.